YD Bio Limited (YDES)
Nasdaq: YDES · Services-Medical Laboratories · Irving, TX · filing with the SEC since 2024
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Apr 30, 2026 | · | · |
| Revenue | 596,817 | 510,360 | 350,131 |
| Cost of revenue | 429,407 | 355,004 | 196,686 |
| Gross profit | 167,410 | 155,356 | 153,445 |
| Research and development | 1,602,064 | 491,353 | · |
| Sales and marketing | 170,523 | 1,957 | 7,492 |
| General and administrative | 3,663,141 | 1,124,469 | 153,069 |
| Total operating expenses | 5,439,131 | 1,617,286 | 163,292 |
| Operating income | -5,271,721 | -1,461,930 | -9,847 |
| Interest expense | · | 772 | 2,144 |
| Interest and investment income | 80,162 | 11,808 | 290 |
| Other income (expense), net | 46,803 | 64,415 | 29,351 |
| Total non-operating income (expense) | -3,041,126 | 75,451 | 27,497 |
| Income before income taxes | -8,312,847 | -1,386,479 | 17,650 |
| Income tax expense | -1,531 | 25,080 | 4,090 |
| Net income | -8,311,316 | -1,411,559 | 13,560 |
| Earnings per share, basic | -0.12 | -0.02 | 0.00 |
| Earnings per share, diluted | -0.12 | -0.02 | 0.00 |
| Weighted average shares, basic | 66,719,177 | 64,730,411 | 64,730,411 |
| Weighted average shares, diluted | 66,719,177 | 64,730,411 | 64,730,411 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSales and marketing the cost of finding and serving customers
us-gaap:SellingAndMarketingExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding